Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Azilsartan Medoxomil Tablets, 40 mg and 80 mg, to market a generic equivalent of Edarbi® Tablets, 40 mg and 80 mg, of Azurity Pharmaceuticals, Inc. The product will be manufactured at Lupin's facility in Nagpur, India.
Azilsartan Medoxomil Tablets (RLD Edarbi®) had estimated annual sales of USD 101 million in the U.S. (IQVIA MAT March 2022).
Shares of Lupin Limited was last trading in BSE at Rs. 632.80 as compared to the previous close of Rs. 639.25. The total number of shares traded during the day was 18845 in over 1302 trades.
The stock hit an intraday high of Rs. 642.95 and intraday low of 626.00. The net turnover during the day was Rs. 11943569.00.